Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Baricitinib in preparation of medicament for treating senile calcific heart valve disease

A valvular disease and drug technology, applied in the field of baricitinib, can solve the undisclosed problems of baricitinib in the elderly with calcific valvular heart disease, achieve the effect of reducing various indicators, improving the condition, and improving the quality of life

Inactive Publication Date: 2019-10-15
HUISHENG MEDICAL TECH XUZHOU CO LTD
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It can be seen that the existing patents do not disclose that baricitinib can treat senile calcific valvular heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Baricitinib in preparation of medicament for treating senile calcific heart valve disease
  • Application of Baricitinib in preparation of medicament for treating senile calcific heart valve disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Effect of baricitinib on the proliferation and apoptosis of rat vascular smooth muscle cells (VSMCs)

[0026] 1. Materials and methods

[0027] 1.1 Experimental method

[0028] The tyrosine kinase inhibitor baricitinib was applied to rat VSMCs, and the cell proliferation was detected by MTT method; the apoptosis of VSMCs was detected by flow cytometry.

[0029] 1.2 Statistical methods

[0030] Application of SPSS10.0 statistical software, independent samples t test.

[0031] 2. Results

[0032] 2.1 The effect of baricitinib on the proliferation level of VSMCs

[0033] At 24, 48, and 72 hours after different concentrations of baricitinib were added to the culture medium, the proliferation level of VSMCs decreased, and the proliferation level of VSMCs decreased with the increase of baricitinib concentration. The results are shown in Table 1.

[0034] Table 1 Effect of different time and concentration of AG490 on the proliferation rate of rat VSMCs

[0035]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to new application of a medicament, in particular to application of Baricitinib in preparation of a medicament for treating senile calcific heart valve disease. The research of the invention shows that: by inhibiting a JAK pathway and selectively activating a substrate-STAT of the Baricitinib, the substrate-STAT is translocated to the nucleus so as to act on downstream targetgenes such as cyclin D1, BCL-xL, C-MYC, P21 WAF1 / CIP1 and the like, and the cell proliferation, differentiation and apoptosis is regulated, so that degeneration, fibrosis, thickening and calcification of heart valve connective tissues of a patient are obviously improved, and cardiomyocytes are protected. Compared with the prior art, the medicament can reduce various indexes of patients with thesenile calcific heart valve disease, improve the disease condition and improve the life quality of the patients with the senile calcific heart valve disease.

Description

technical field [0001] The present invention relates to a new application of baricitinib, in particular to the application of baricitinib in the preparation of medicines for treating senile calcific heart valve disease. Background technique [0002] With the prolongation of life expectancy and the greatly reduced incidence of acute rheumatic fever, the incidence of elderly calcific valvular heart disease and its proportion in the disease spectrum have increased significantly. With the advancement of diagnostic methods such as ultrasound diagnostics, making It is possible to obtain a diagnosis of the disease before death. [0003] More than 90% of aortic stenosis in the elderly aged 65 and over is caused by aortic valve calcification, and about 52% of aortic insufficiency. Domestic reports have shown that the incidence of calcific valvular heart disease in the elderly is about 3.64%, and that of those over 60 years old is 8.62%. This cause of heart valve disease in the elde...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/519A61K45/06A61P9/00
CPCA61K31/519A61K45/06A61P9/00
Inventor 何松繁
Owner HUISHENG MEDICAL TECH XUZHOU CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com